Pharmacokinetics of cisplatin in analbuminemic rats

Takada, Kanji; Kawamura, T.; Inai, Maya; Masuda, Shin; Oka, Takahiro; Yoshikawa, Yukako; Shibata, Nobuhito; Yoshikawa, Hiroshi; Ike, Osamu; Wada, Hiromi; Hitomï, Shigeki

doi:10.1002/1099-081x(199912)20:9<421::aid-bdd206>3.3.co;2-0

Cited by 6 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results suggest that the volume of distribution of oxaliplatin is larger than that of cisplatin. Platinum agents are reported to bind to the drug binding sites of albumin, cysteine residues of constituent amino acids and methionine residues (Bell et al, ; Lokich & Anderson, ; Takada et al, ; Xie et al, ; Yee, Pater, & Pho, ). Because most of the cisplatin with albumin binding was irreversible, it was considered that the bonds formed between cisplatin and albumin amino‐acid residues were most likely covalent bonds.…”

Section: Resultsmentioning

confidence: 99%

“…Package inserts state the high protein binding rates of cisplatin, carboplatin and oxaliplatin as 98%, 25%–50% and 98%, respectively. Reports also indicate that the binding of cisplatin and oxaliplatin to proteins is irreversible (Bell et al, ; Benedetti et al, ; Takada et al, ). Conversely, carboplatin is reported to be less reactive and more stable, and therefore tends to be more loosely bound to proteins.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma‐mass spectrometory

Kato

Sato

Iwamoto

et al. 2019

Biopharm & Drug Disp

View full text Add to dashboard Cite

The protein binding rates (PBR) of platinum‐containing agents cisplatin (CDDP), carboplatin (CBDCA) and oxaliplatin (L‐OHP) have been reported as 98%, 25–50% and 98%, respectively. To investigate the protein‐binding properties of albumin with cisplatin, carboplatin and oxaliplatin, inductively coupled plasma mass spectrometry (ICP‐MS) was used to measure their plasma concentration in rats over time. The study also examined the effects of cisplatin, carboplatin and oxaliplatin‐binding on albumin in vitro, using CD spectrometry and native‐polyacrylamide gel electrophoresis (native PAGE). The ratios of PBR to irreversible PBR, of cisplatin and oxaliplatin were 98%:98% and 90%:87%, respectively, indicating a higher affinity for irreversible binding with albumin. That of carboplatin was 25%:10%, indicating 60–70% reversible binding with albumin. The plasma protein binding rate concentrations of cisplatin, carboplatin and oxaliplatin after in vivo administration were 96%, 15% and 80%, respectively. The CD spectrometry of albumin was unaffected by cisplatin, carboplatin and oxaliplatin binding. Though similar protein binding rates were observed with oxaliplatin and cisplatin, oxaliplatin had a higher mobility rate during PAGE. It was confirmed that the binding of cisplatin and oxaliplatin with albumin affected its electric charge but not the structure. In conclusion, cisplatin and oxaliplatin bind irreversibly with albumin in plasma and may irreversibly interact with tissue protein and/or DNA. The difficulties involved with predicting the tissue concentrations of cisplatin and oxaliplatin from their plasma concentration inhibits their therapeutic drug monitoring. On the contrary, carboplatin, like some generic drugs, reversibly binds to plasma proteins. It is, therefore, possible to conduct therapeutic drug monitoring for carboplatin.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma‐mass spectrometory

Kato

Sato

Iwamoto

et al. 2019

Biopharm & Drug Disp

View full text Add to dashboard Cite

show abstract

“…Bioanalytical determination of cisplatin is most often based on non-selective techniques, targeting the Pt, which cannot distinguish between different Pt-containing complexes. These non-selective techniques include phosphorescence [18], X-ray fluorescence [19], atomic absorption spectroscopy (AAS) [20][21][22] and inductively coupled plasma-mass spectrometry (ICP-MS) [23][24][25]. ICP-MS is the most frequently used tool for the measurement of total platinum for the drug cisplatin [14,26].…”

Section: Introductionmentioning

confidence: 99%

Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

Xie

Colin

Bocxlaer

2017

Talanta

View full text Add to dashboard Cite

Cisplatin is a first-line chemotherapeutic for the treatment of a wide variety of cancers since its discovery in the 1960s. Although various techniques have been reported for the measurement of total platinum in biological matrices, such as inductively coupled plasma-mass spectrometry and derivatization procedures, a specific, sensitive and robust assay for the quantification of intact cisplatin is still lacking. Therefore, we present a rapid, selective, sensitive, and reliable UHPLC-MS/MS based method for the determination of intact cisplatin in human plasma in support of a Phase II clinical trial. The optimal chromatographic behavior of cisplatin was achieved on a Syncronis HILIC column (50 × 2.1mm, 1.7µm, zwitterionic stationary phase). The retention behavior of cisplatin on this zwitterion-based stationary phase was well described by an adsorptive interaction model. A simple sample preparation based on protein precipitation combined with the removal of phospholipids by HybridSPE-precipitation was developed. The method was proven to be free of a relative matrix effect. The assay was validated within a range of 20 - 10,000ng/mL using 100μL of plasma sample. The intra and inter-day precisions were all less than 7.6%, and none of the bias was greater than 13.1%, thus corroborating that the developed method is precise and accurate. As a proof of concept, the assay has been successfully applied to plasma samples obtained from different patients who were enrolled in the Phase II trial and were treated with cisplatin.

show abstract

“…Cisplatin (cis-diamminedichloroplatinum, CP) is an effective anticancer agent in head/neck, lung, cervical and bladder cancers [1]. However, the use of CP is limited by severe side effects in normal tissues including the kidney [2].…”

Section: Introductionmentioning

confidence: 99%

Acute and chronic effects of dietary sodium restriction on renal tubulointerstitial fibrosis in cisplatin-treated rats

Park

Kim

et al. 2012

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

show abstract

Pharmacokinetics of cisplatin in analbuminemic rats

Cited by 6 publications

References 0 publications

Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma‐mass spectrometory

Interaction of platinum agents, cisplatin, carboplatin and oxaliplatin against albumin in vivo rats and in vitro study using inductively coupled plasma‐mass spectrometory

Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma

Acute and chronic effects of dietary sodium restriction on renal tubulointerstitial fibrosis in cisplatin-treated rats

Contact Info

Product

Resources

About